Gliadorphin: wheat gluten fragment linked to autism and schizophrenia
A small peptide released when wheat gluten is incompletely digested; it activates the brain's opioid receptors, and elevated levels have been found in people with autism, schizophrenia, and celiac disease. Used only as a lab research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Gliadorphin-7 (also called gluteomorphin or alpha-gliadin 43–49) is a seven-amino-acid fragment released during the digestion of gliadin, a protein found in wheat gluten. Unlike the body's own opioid peptides, gliadorphin-7 is an exogenous opioid — it comes from food, not from the body's own signalling systems. Under normal digestive conditions it is rapidly broken down into individual amino acids, but when proteolytic processing is incomplete, the intact peptide can persist in the gut and potentially enter the bloodstream. Elevated levels have been detected in the urine of individuals with autism, and the peptide's presence has been linked in the research literature to autism spectrum disorder, schizophrenia, and celiac disease.
History
The broader field of food-derived opioid peptides — called exorphins — was established in the late 1970s, when researchers first demonstrated that pepsin hydrolysates of wheat gluten and casein contained short peptides with naloxone-reversible opioid activity. The specific connection between gluten-derived peptides and neuropsychiatric disease has a longer history: F. C. Dohan proposed as early as 1966 that cereal grain consumption might contribute to schizophrenia susceptibility, an observation that gained traction when studies reported reduced psychotic symptoms in schizophrenic patients on cereal-free diets. Fukudome and Yoshikawa (FEBS Letters, 1992) characterised multiple opioid peptides from enzymatic digests of wheat gluten. Specific interest in gliadorphin-7 as a candidate in autism emerged from the opioid-excess hypothesis, developed and updated by Shattock, Whiteley, and colleagues, which proposed that incomplete digestion of dietary gluten and casein releases opioid-active fragments that cross the intestinal wall and reach the brain in susceptible individuals. Sun and colleagues (Peptides, 2003) were among the first to directly administer gliadorphin-7 to animals and characterise its central effects.
What it does
Gliadorphin-7 acts as an agonist at opioid receptors — primarily the mu-opioid receptor (OPRM1), the same class of receptor targeted by opioid analgesics and endorphins — and shows some activity at delta-opioid receptors as well (Sun et al., Peptides, 2003). Because the peptide contains multiple proline residues, it resists degradation from the C-terminus, which contributes to its persistence when the enzyme dipeptidyl peptidase IV (DPP-IV) — which cleaves N-terminal dipeptides with proline at the second position — is deficient or reduced in activity. In the gut, elevated gliadorphin-7 may affect motility and intestinal permeability. If the peptide reaches the brain, it can interact with opioid receptors in neural circuits involved in behaviour, attention, and sensory processing.
Evidence
- Human: Abnormally elevated gliadorphin-7 levels have been detected by mass spectrometry in urine from children with autism spectrum disorder, and elevated levels have also been reported in individuals with schizophrenia (Christison and Ivany, J Dev Behav Pediatr, 2006; multiple opioid-excess hypothesis studies). The association between these elevated levels and symptom severity has been investigated in several studies, though results are inconsistent. No controlled clinical trials of gliadorphin-7 itself have been registered on ClinicalTrials.gov.
- Animal: Sun and colleagues (Peptides, 2003) infused gliadorphin-7 into rats and found dose-related immunoreactivity (Fos-like immunoreactivity, FLI) in the geniculate nuclei and the alveus hippocampus. These effects were largely blocked by naloxone (2 mg/kg), confirming opioid receptor mediation. Notably, unlike beta-casomorphin-7, gliadorphin-7 produced no overt behavioural changes in rats even at doses that activated these brain regions.
- In vitro: Both gliadorphin-7 and beta-casomorphin-7 have been shown to decrease cysteine uptake in cultured human neuronal and gastrointestinal epithelial cells via opioid receptor activation, with beta-casomorphin-7 showing stronger effects (reviewed in Casomorphins and Gliadorphins Have Diverse Systemic Effects, PMC8345738).
Known effects
- Mu-opioid receptor activation — demonstrated in rat models; naloxone-reversible (Sun et al., 2003)
- Brain region activation (geniculate nuclei, alveus hippocampus) — preclinical, rat infusion model (Sun et al., 2003)
- Reduced neuronal cysteine uptake — in vitro, human neuronal cell cultures
- Elevated urine levels in autism — human observational studies; causal role not established
- Association with schizophrenia — elevated urine peptides reported; mechanism speculative
Mechanism
Gliadorphin-7 (YPQPQPF) is the seven-residue fragment spanning positions 43–49 of alpha-gliadin. Its N-terminal tyrosine-proline motif is characteristic of opioid peptides that bind the mu-opioid receptor; the tyrosine hydroxyl makes a key contact with the receptor's binding pocket, an interaction shared with endogenous opioids like met-enkephalin. The multiple internal proline residues confer resistance to carboxypeptidase degradation. DPP-IV, which cleaves X-Pro dipeptides from N-termini, is the primary enzyme responsible for inactivating gliadorphin-7; reduced DPP-IV activity — reported in serum from some children with autism — could allow the peptide to persist and accumulate (PMC7407635).
Once in circulation, gliadorphin-7 is thought to reach the brain primarily through diffusion across circumventricular organs rather than by active carrier-mediated transport across the blood–brain barrier, distinguishing its central access mechanism from the carrier-facilitated pathway proposed for beta-casomorphin-7 (Sun et al., Peptides, 2003).
Safety signals
No clinical safety data exist for gliadorphin-7 as an administered compound. Its relevance to human health has been studied in the context of dietary exposure. The opioid-excess hypothesis linking elevated gliadorphin to autism and schizophrenia remains contested; a subset of studies using liquid chromatography–mass spectrometry did not detect opioid peptides in urine from autistic children, raising questions about the reliability of earlier detection methods.
Regulatory status
- US: No FDA regulatory status; not approved as a drug or therapeutic agent. Exists as a research peptide and reagent.
- EU: Not approved or regulated as a pharmaceutical.
- Research use: Commercially available as a synthetic research standard (CAS 107936-65-2).
Related peptides
- Beta-casomorphin-7 — the milk-derived counterpart in the opioid-excess hypothesis; also a mu-opioid agonist released during casein digestion, but with broader brain region activation and more pronounced behavioural effects in rat models than gliadorphin-7
- Gluten exorphins A5, B5 (GYYPT, YGGWL) — related wheat-derived opioid peptides isolated by Fukudome and Yoshikawa (1992); primarily delta-opioid receptor activity, structurally distinct from gliadorphin-7
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does the wheat-derived peptide gliadorphin-7 flip the opioid receptor into a mode that mainly slows the gut rather than producing pain relief or a mood effect?
If true, it could explain why some people with autism or celiac disease have gut dysmotility after eating wheat, and might reveal a drug-free dietary route to managing opioid-receptor-driven gut problems.
Does gliadorphin-7 bind the mu-opioid receptor more tightly than the other two main opioid receptors in the brain?
If the selectivity is confirmed, it would tell researchers exactly which receptor to target, or block, when trying to prevent neurological symptoms associated with wheat consumption in vulnerable individuals.
If someone has both a leaky gut and a more permeable blood-brain barrier, can gliadorphin-7 reach the reward centres of the brain and make wheat feel addictive?
If true, it would explain why gluten-free diets help some people with autism or schizophrenia and shift treatment focus toward healing the gut barrier, which might be more achievable than permanently avoiding all wheat.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.9371911287307739 | boltz-2 |
| ranking score | 0.8029004335403442 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.932 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep10714,
sequence = {YPQPQPF},
target = {oprm1},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}